HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank Tacke Selected Research

Neuroendocrine Tumors (Neuroendocrine Tumor)

8/2021The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors.
1/2021PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study.
1/2021A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report.
6/2020A case report of an excellent response to interferon- α in a patient with functional metastasized neuroendocrine tumor refractory to other treatments.
5/2020Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
6/2019Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank Tacke Research Topics

Disease

102Inflammation (Inflammations)
10/2022 - 06/2003
92Fibrosis (Cirrhosis)
11/2022 - 04/2002
82Liver Cirrhosis (Hepatic Cirrhosis)
10/2022 - 06/2002
66Neoplasms (Cancer)
06/2022 - 05/2010
60Liver Diseases (Liver Disease)
10/2022 - 04/2002
52Critical Illness (Critically Ill)
12/2021 - 08/2008
46Sepsis (Septicemia)
08/2021 - 08/2008
35Infections
01/2022 - 04/2002
30Non-alcoholic Fatty Liver Disease
10/2022 - 01/2014
30Hepatocellular Carcinoma (Hepatoma)
10/2022 - 04/2003
15Fatty Liver
06/2022 - 05/2005
14Liver Neoplasms (Liver Cancer)
11/2021 - 05/2010
14Hepatitis
01/2021 - 04/2002
11Obesity
06/2022 - 01/2009
11Insulin Resistance
04/2021 - 05/2005
10Disease Progression
01/2022 - 08/2007
10Hemorrhage
10/2021 - 04/2003
9Alcoholic Fatty Liver
06/2022 - 03/2012
9Hepatitis C
01/2022 - 01/2010
9COVID-19
01/2022 - 01/2020
9Hepatitis B
01/2019 - 04/2002
8Neoplasm Metastasis (Metastasis)
10/2021 - 04/2016
8Acute Liver Failure (Fulminant Hepatic Failure)
01/2018 - 04/2008
7Renal Insufficiency (Renal Failure)
01/2019 - 01/2009
7Necrosis
07/2018 - 12/2011
6Sclerosing Cholangitis
04/2022 - 01/2017
6End Stage Liver Disease
03/2022 - 06/2006
6Neuroendocrine Tumors (Neuroendocrine Tumor)
08/2021 - 06/2019
6Portal Hypertension
06/2021 - 07/2003
6Colitis
07/2018 - 09/2008
5Cholangiocarcinoma
06/2022 - 01/2016
5Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
01/2022 - 01/2011
5Type 2 Diabetes Mellitus (MODY)
01/2022 - 01/2009
5Atherosclerosis
10/2021 - 03/2006
5Chronic Hepatitis B
01/2021 - 08/2004
4Chronic Hepatitis C
01/2022 - 02/2008
4Reperfusion Injury
10/2021 - 06/2003
4Pancreatic Neoplasms (Pancreatic Cancer)
06/2021 - 07/2018
4Cholestasis
01/2021 - 05/2005
4Communicable Diseases (Infectious Diseases)
09/2019 - 01/2014

Drug/Important Bio-Agent (IBA)

72Biomarkers (Surrogate Marker)IBA
06/2022 - 07/2003
36CytokinesIBA
01/2021 - 09/2008
31ChemokinesIBA
01/2022 - 11/2006
24Chemokine ReceptorsIBA
06/2022 - 03/2006
21Proteins (Proteins, Gene)FDA Link
01/2022 - 04/2007
20LigandsIBA
11/2022 - 08/2007
19MicroRNAs (MicroRNA)IBA
01/2022 - 01/2011
14Antiviral Agents (Antivirals)IBA
07/2022 - 06/2014
13Pharmaceutical PreparationsIBA
06/2022 - 08/2004
13Urokinase Plasminogen Activator ReceptorsIBA
04/2022 - 01/2011
12CollagenIBA
01/2021 - 09/2009
11Interleukin-6 (Interleukin 6)IBA
01/2021 - 07/2003
10Glucose (Dextrose)FDA LinkGeneric
01/2022 - 05/2007
9Choline (Choline Chloride)IBA
06/2022 - 01/2014
9RNA (Ribonucleic Acid)IBA
01/2022 - 01/2016
9InterferonsIBA
01/2021 - 10/2004
9Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2021 - 06/2006
9Carbon Tetrachloride (Tetrachloromethane)IBA
01/2019 - 11/2010
8Immune Checkpoint InhibitorsIBA
03/2021 - 06/2020
8AdipokinesIBA
12/2019 - 05/2007
8Methionine (L-Methionine)FDA Link
01/2019 - 01/2014
7Peroxisome Proliferator-Activated Receptors (PPAR)IBA
10/2022 - 12/2014
7cenicrivirocIBA
01/2022 - 01/2018
7OsteopontinIBA
08/2021 - 01/2015
7AdiponectinIBA
12/2019 - 05/2005
6Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
06/2022 - 02/2011
6CC ChemokinesIBA
01/2022 - 08/2007
6Messenger RNA (mRNA)IBA
09/2021 - 06/2002
6C-Reactive ProteinIBA
03/2021 - 06/2006
6Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2021 - 04/2007
6Peptides (Polypeptides)IBA
01/2020 - 04/2012
6ResistinIBA
12/2019 - 06/2006
5LipidsIBA
10/2022 - 10/2016
5Triglycerides (Triacylglycerol)IBA
06/2022 - 03/2012
5AntibodiesIBA
01/2022 - 01/2017
5Bile Acids and Salts (Bile Acids)IBA
01/2022 - 01/2018
5Tumor Biomarkers (Tumor Markers)IBA
10/2021 - 05/2011
5IntegrinsIBA
08/2021 - 12/2014
5DNA (Deoxyribonucleic Acid)IBA
01/2021 - 08/2006
4Protein Kinases (Protein Kinase)IBA
10/2022 - 01/2016
4Amino AcidsFDA Link
06/2022 - 05/2020
46-propylchromone-2-carboxylic acid (PCCA)IBA
04/2022 - 08/2019
4Insulin (Novolin)FDA Link
01/2022 - 04/2003
4Dexamethasone (Maxidex)FDA LinkGeneric
01/2022 - 01/2015
4Extracellular Matrix ProteinsIBA
04/2021 - 09/2009
4Hepatitis B e AntigensIBA
01/2021 - 08/2004
4Somatostatin Receptors (Somatostatin Receptor)IBA
01/2021 - 01/2020
4AntigensIBA
01/2021 - 01/2014
4Acetaminophen (Paracetamol)FDA LinkGeneric
01/2020 - 01/2012
4Retinol-Binding Proteins (Retinoid Binding Proteins)IBA
12/2019 - 05/2007
4Liposomes (Liposome)IBA
01/2019 - 08/2014
4Caspase 8 (Caspase-8)IBA
01/2017 - 12/2011
4Apolipoproteins E (ApoE)IBA
08/2015 - 03/2006

Therapy/Procedure

74Therapeutics
10/2022 - 10/2004
23Liver Transplantation
06/2022 - 03/2006
12Ligation
10/2021 - 05/2005
9Critical Care (Surgical Intensive Care)
02/2022 - 01/2009
7Transplantation
10/2022 - 02/2010
5Immunotherapy
01/2021 - 10/2017
4Drug Therapy (Chemotherapy)
05/2021 - 03/2018